What is the role of GLP-1 RAs in managing obstructive sleep apnea?

Obstructive sleep apnea (OSA) affects nearly 1 billion adults worldwide. Untreated OSA is independently associated with hypertension, cardiovascular disease, stroke, motor vehicle accidents and increased all-cause mortality. Continuous positive airway pressure (CPAP) is the standard treatment, but its effectiveness is limited by adherence rates of only 30%–60%. Obesity is the primary modifiable risk factor and is present in 60%–70% of patients with OSA. Until recently, no pharmacologic therapies specifically targeted this pathophysiologic mechanism.1 Health Canada approved tirzepatide (Zepbound) in June 2026 (and US Food and Drug Administration in December 2024) as the first medication indicated for moderate to severe OSA in adults with obesity. Tirzepatide is a dual receptor agonist for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), and induces substantial weight loss by centrally-mediated appetite suppression. The approval of tirzepatide for OSA represented a shift from solely mechanical symptom management (with CPAP) to pharmacologic approaches for disease modification.1,2 Other GLP-1 RAs (e.g., liraglutide, semaglutide) have also demonstrated improvements in OSA, but have not yet been approved by Canadian or U.S. regulatory authorities for this therapeutic indication.1 Weight loss is the primary established mechanism of benefit of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in OSA, with GLP-1 RAs reducing tongue fat and parapharyngeal adipose tissue that contribute to upper airway collapse. Emerging preclinical evidence also suggests potential weight-independent mechanisms of action for GLP-1 RAs through carotid body glucagon-like peptide 1 receptor modulation of chemosensitivity, leptin pathway interactions that are associated with upper airway neuromuscular control, and NLRP3 inflammasome suppression (see reference #1 for a more detailed discussion of these proposed mechanisms).1 Six meta-analyses have demonstrated consistent apnea-hypopnea index (AHI) reductions with GLP-1 RAs, ranging from −5.7 to −21.9 events per hour. The SURMOUNT-OSA phase 3 trials showed that tirzepatide reduced AHI by 20–24 events per hour vs placebo, with 42%–50% of patients experiencing disease remission (i.e., AHI, < 5 events/hour or < 15/hour without symptoms). However, GLP-1 RAs do not match CPAP effectiveness. Meta-analyses have shown that CPAP reduces AHI by approximately 31 events/hour compared with tirzepatide (about 22 events/hour), a 30% greater reduction with CPAP. For patients with severe OSA who need immediate symptom relief or have substantial hypoxemia, CPAP remains more effective. In addition, cardiovascular outcome benefits of tirzepatide remain unproven and weight regain commonly occurs after tirzepatide discontinuation.1Overall, GLP-1 RAs offer a disease-modifying adjunct for obesity-related OSA and are best positioned as a complementary therapy alongside CPAP. They represent a substantial advancement in OSA treatment, producing clinically meaningful reductions in AHI, with tirzepatide showing a 50%–63% decrease in severity and 42%–50% remission rates.1 GLP-1 RAs can also be used preoperatively before upper airway surgery in OSA to improve outcomes, or potentially used to expand hypoglossal nerve stimulator candidacy. They are appropriate for patients with a body mass index > 30 and who are CPAP-intolerant or have obesity-related comorbidities. GLP-1 RAs are unlikely to benefit individuals without obesity or those with primarily anatomical obstruction. A significant percentage of patients with OSA do not have obesity and these individuals may have primarily anatomical (e.g., tonsillar hypertrophy, retrognathia) or central sleep apnea, which are unlikely to respond to weight loss strategies.1ReferencesHarris A, Kaffenberger T. Glucagon-like peptide-1 receptor agonists for obstructive sleep apnea. A review. JAMA Otolaryngol Head Neck Surg 2026; published online: September 3, 2026. (accessed September 4, 2026).Eli Lilly Canada Inc. Zepbound (tirzepatide injection) product monograph. Toronto, ON; June 11, 2026. (accessed September 4, 2026).

What is the role of GLP-1 RAs in managing obstructive sleep apnea?

Register for free access or login.

Related Topics